An app that is closely related to the development of UNR844 presbyopia-correcting ophthalmic solution from Novartis effectively measures vision changes at home, monitoring the effects and potentially warning the patient when it is time to repeat the treatment.
“Within our clinical studies, vision is measured in the clinic with the traditional tests, then with the app, and then the app is used at home. One of our goals is to verify if results are the same. This is a validation test, which is key to our study design for UNR844,” (Read more...)
Uncategorized